6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial

I.Lang; C.H.K?hne; G.Folprecht; M.P.Nowacki; S.Cascinu; I.Shchepotin; J.Maurel; D.Cunningham; A.Zubel; E.Van Cutsem

首页> 外文期刊>European Journal of Cancer Supplements >6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial

【24h】

6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial

机译：6078西妥昔单抗联合FOLFIRI在转移性结直肠癌的一线治疗中：CRYSTAL试验中患有KRAS野生型（wt）肿瘤的患者（pts）的生活质量（QoL）分析

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements 》 |2009年第2期| 共1页
作者
I.Lang; C.H.K?hne; G.Folprecht; M.P.Nowacki; S.Cascinu; I.Shchepotin; J.Maurel; D.Cunningham; A.Zubel; E.Van Cutsem;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献

1. 6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4+/- cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study [J] . C.Bokemeyer, I.Bondarenko, J.T.Hartmann, European Journal of Cancer Supplements . 2009 ,第2期

机译：OPUS研究：FOLFOX4 +/-西妥昔单抗作为转移性结直肠癌一线治疗的6079名KRAS野生型肿瘤患者的总生存期：
2. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306 [J] . PietrantonioF., GarassinoM.C., TorriV., Annals of oncology: official journal of the European Society for Medical Oncology . 2012 ,第10期

机译：答复德国AIO随机研究KRK-0306中FOLFIRI加西妥昔单抗与FOLFIRI加贝伐单抗作为转移性结直肠癌患者一线治疗的KRAS突变肿瘤患者亚组分析
3. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: Mutated tumours in the randomised German AIO study KRK-0306 [J] . StintzingS., FischervonweikersthalL., DeckerT., Annals of oncology: official journal of the European Society for Medical Oncology . 2012 ,第7期

机译：FOLFIRI加西妥昔单抗与FOLFIRI加贝伐单抗作为转移性结直肠癌患者一线治疗的KRAS患者亚组分析：德国AIO随机研究KRK-0306中的突变肿瘤
4. Correlations between depressive symptoms and quality of life in metastatic breast cancer patients during chemotherapy [C] . Dragomir B.I., Campean A. European Association of Psychosomatic Medicine., Annual Meeting. . 2014

机译：化疗期间转移性乳腺癌患者抑郁症状与生活质量的相关性
5. Analysis of quality of life data from a clinical trial in patients with advanced breast cancer with a comparison of different statistical approaches. [D] . Liu, Jianhua. 2002

机译：通过比较不同统计方法对晚期乳腺癌患者的临床试验的生活质量数据进行分析。
6. A triplet combination with irinotecan (CPT-11) oxaliplatin (LOHP) continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt metastatic colorectal cancer: a pilot phase II trial [O] . Z Saridaki, N Androulakis, N Vardakis, 2012

机译：三联体联合伊立替康（CPT-11）奥沙利铂（LOHP）连续输注5-氟尿嘧啶和亚叶酸（FOLFOXIRI）加西妥昔单抗作为KRAS转移转移性结直肠癌的一线治疗：一项中试II期试验
7. PCN171 Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia [O] . Vargas-Valencia J, Garcia Perlaza J 2015

机译：帕尼单抗+ Folfox与西妥昔单抗+ Folfiri相比一线治疗PCN171成本效益分析

6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial

著录项

相似文献

相关主题

期刊订阅